Aligos Therapeutics, Inc. announced that the company has started dosing in the first cohort of healthy volunteers in Study ALG-055009-301 evaluating ALG-055009 for the treatment of nonalcoholic steatohepatitis (NASH).
[Aligos Therapeutics, Inc. (Globe Newswire, Inc.)]